DSHEA provides an appropriate structure that balances the risks and benefits to consumers with continued access and affordability." Since enactment of the DSHEA, warnings on several products as causes for liver injury have been issued by the Food and Drug Administration (FDA) (►Table 1). The most recent FDA warnings were for products containing multiple ingredients: Uprizing 2.0, 4 which was found to contain undeclared synthetic steroids, and OxyElite Pro, 5 which has been implicated in several cases of acute liver failure, some resulting in death or liver transplantation. The DSHEA defines a dietary supplement as any product intended to supplement, but not substitute for diet. Dietary supplements may contain one or more ingredients that include vitamins, minerals, herbs, or other botanicals; amino acids; or extracts thereof. The law stipulates that a product's label must accurately reflect its contents. Ostensibly, the act provides the FDA with the authority to monitor the safety of marketed products. Unlike conventional pharmaceuticals, the DSHEA affords no assurance to the consumer as to the effectiveness of a product, maintenance of health, mitigation of disease, or to safety before it becomes available on the market. Subsequent legislation through the Final Rule for Dietary Supplement Current Good Manufacturing Practices (2007) still does not address assurances of safety to the consumer. Rather, this legislation only gives guidance to manufacturers on production standards, including an attestation that a product is free from adulteration and contamination. Essentially, the safety of any marketed dietary supplement is predicated upon a manufacturer's commitment to regulatory adherence. The burden of proof that a product caused harm or of a manufacturer's nonadherence to regulation rests upon the FDA.
One class of supplements, the medical foods, merit special mention because they require the supervision of a prescribing physician.
6 However, they are still regarded as dietary supplements and recognized as such under the DSHEA. They are not regulated with the same rigor as are drugs, having no requirement for preclinical safety testing. A recent case series of liver injury resulting from the medical food Flavocoxib showed that this type of supplement has the capacity to induce liver injury. Across the globe, regulation for HDS is quite varied. In the European Union, regulation is based upon the Traditional Herbals Medicine Products Directive 2004/24/EC. 8 This regulation stipulates that products could be licensed for use following a simplified registration procedure if there was an acceptably long period of demonstrated safety, specifically 15 years in the European Union (EU) and 30 years total, are not used parenterally, and do not require a medical prescription. After May 1, 2011, all unlicensed herbal medicinal products presented as having properties for treating or preventing disease in humans or where it has a pharmacological, immunological, or metabolic action must have been either marketed as medicines or withdrawn from the market. Unlike the FDA, the European Medicines Agency has the purview of herbal medicinal products only. Products considered food supplements or cosmetics are overseen by the European Food Safety Authority (EFSA), the appointed authority in the EU. A Committee on Herbal Medicinal Products (HMPC), 9 comprised of scientific experts in the field of herbal medicines from various disciplines, was established within the European Medicines Agency in September 2004 to develop a list of herbal substances, preparations, and combinations thereof that are used in traditional herbal medicinal products. The HMPC was also charged with creating a library of monographs containing information on composition, indications and contraindications, safety, and pharmacological properties for products with well-established use. 10 In the United Kingdom (UK), the Herbal Medicines Advisory Committee was established to advise on the safety, quality, and efficacy of herbal medicinal products eligible for registration under the EU's regulation, as well as other unlicensed herbal products.
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Beyond what is discussed above, there are no other broadly applied regulatory standards for HDS. In fact, the World Health Organization (WHO) in 2001 polled 191 member states and found that of 141 respondents, only 53 (38%) had some legislation governing HDS use. 12 The WHO has taken on the challenge of protecting and promoting public health and safety, globally, 13 through improved regulation of herbal medicines with the creation of the International Regulatory Cooperation for Herbal Medicines (IRCH) in 2006. 14 
The Prevalence of Use and Commerce Attributable to Herbal and Dietary Supplements
The earliest reliable survey in the United States regarding the use of alternative medicine showed that 34% of those polled 
20
The rise in use of HDS parallels an increase in commerce. Total sales of herbals and botanical dietary supplements in the United States have risen consistently over the past 9 years to $5.5 billion in 2012. 21 Globally, expenditures are expected to reach $107 billion in 2017. 22 Although accurate U.S. or global statistics on actual use of HDS are not available, one can infer that there has been an increase based on this rising HDS commerce.
Epidemiology of Liver Injury due to Herbal and Dietary Supplements
The epidemiology of liver injury due to HDS is largely unknown, but is likely to be strongly influenced by type of supplement, geography, and cultural acceptance. As stated earlier, use of HDS is an integral part of medical care in Africa. Similar commonplace use may be seen in Southeast Asia, and in Central and South America where there also is a long history of traditional herbal medicine. The true prevalence and incidence of hepatotoxicity due to HDS cannot be estimated because of the unavailability of a denominator, the number of persons in a population who consume them. Accurate estimates based on sales are hindered by the many places where one can obtain HDS, such as health food stores, the Internet, and gymnasiums. Even in the elegant population-based prospective 2-year cohort study on the incidence of hepatotoxicity in Iceland in which HDS accounted for 16% of cases, the true impact of hepatotoxicity from natural products could not be determined.
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Information on liver injury due to HDS has come mainly from published case reports or case series. However, inferences on its relative frequency could be made from prospective drug-induced liver injury (DILI) cohorts and retrospective databases that capture hepatotoxicity cases due to HDS (►Table 2). National and international DILI registries such as U.S. Drug-Induced Liver Injury Network (DILIN), the Spanish DILI Registry, and Spanish-Latin American DILI network (SLATINDILI) found 9%, 6%, and 8% of their liver injury cases were due to HDS, respectively. [24] [25] [26] However, in Southeast Asia, HDS are a more prominent cause of liver injury. In a Korean collaboration among 17 hospitals, 73% of all DILI cases were due to HDS. 27 Similarly, a single-hospital study in Singapore reported 71% of liver injury cases were due to HDS. Interestingly, 9 of 31 complementary and alternative medicines identified as causal agents in this study were found to contain adulterants, including pharmaceuticals such as codeine, dexamethasone, and paracetamol.
28
The prevalence of liver injury due to HDS relative to medications has also been demonstrated in a retrospective analysis of patients seen in a single Chinese gastroenterology unit, with 40% of the recorded cases being caused by HDS.
29
Interestingly, less than 2% of 313 liver injury patients seen in an Indian single center were caused by HDS. The authors speculated that this low frequency was due to both the more common use of HDS after liver injury onset and the health system organization in India, which has a network of specialized medical centers accustomed to, and perhaps less likely to report, the use and adverse events associated with HDS.
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The frequency of liver injury caused by nonprescription performance-enhancing products possibly tainted with or functioning as androgenic anabolic steroids reported both in the DILIN and the Spanish DILI registries is a growing concern. In the DILIN registry, the proportion of cases attributed to HDS increased from 7% in 2004 to 2005 to 20% in 2010 to 2012 and the increase occurred with bodybuilding (2-7%) as well as other HDS (5-12%). 31 Similarly, in a span of 19 years in the Spanish-DILI Registry, 80% (20/25) of the cases of liver injury due to anabolic steroids occurred in the most recent 3 years of the study (unpublished data). Among cases of liver injury due to HDS enrolled in prospective registries, 1.5 to 11% have been reported to result in acute liver failure (ALF), underscoring the life-threatening potential of some HDS (►Table 2). Furthermore, HDS, nonprescription medications, weight-loss treatments, and illicit substances were responsible for 10.6% of ALF cases, and ranked second only to antimicrobials as a cause for ALF in the U.S. Acute Liver Failure Study group during a 10-year period.
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Hepatotoxicity due to HDS is believed to be underdiagnosed. Underreporting probably occurs due to lack of awareness of their hepatotoxic potential and patient reluctance to report use of HDS. Based on a 2007 national health survey, only 43.5% of consumers of HDS disclosed their use to their provider. 33 Besides impeding a correct diagnosis in hepatotoxicity due to HDS, concomitant use of HDS can increase the risk of adverse reaction by interaction with concomitantly used medications.
Clinical Presentation
The liver biochemistry pattern of hepatotoxicity due to HDS can be categorized as hepatocellular, cholestatic, or mixed pattern, similar to the way drug-induced injury is described. However, the hepatocellular pattern of injury seems more frequent than with conventional medications, ranging from 63 to 89% across the prospective registries (►Table 2) and reaching 93% in the ALFSG experience (vs. 77% attributable to 
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The spectrum of clinical features resulting from hepatotoxicity due to HDS is quite broad. Acute and chronic hepatitis with autoimmune features, hepatic fibrosis, cirrhosis, zonal or diffuse hepatic necrosis, microvesicular steatosis, giant cell hepatitis, cholestatic hepatitis, bile duct injury, veno-occlusive disease, fulminant liver failure, and carcinogenesis have all been described. 36, 37 The autoimmune phenotype may be more common with injury from HDS, occurring in up to 44% of the cases in one series. 26 Patients with hepatotoxicity due to HDS tend to be younger than those with hepatotoxicity from conventional medications, probably because younger people more commonly take certain HDS, such as "fat burning," weight-loss, and body-building agents. No information in pediatric populations is available and may be either underreported across the registries or there is less use of HDS. Rechallenge, either inadvertent or voluntary, is more common with HDS consumption ranging from 9 to 11% as compared with 6% in an analysis of 520 DILI cases included in the Spanish registry.
38

Diagnosis
Making an accurate diagnosis of hepatotoxicity attributable to HDS is predicated upon the same stepwise approach as is followed for conventional drug-related hepatotoxicity, and discussed elsewhere in this issue of Seminars. At the outset, the astute clinician must recognize that hepatotoxicity need not present with obvious signs of liver injury such as jaundice or encephalopathy. Rather, liver injury can present in much more subtle ways, such as with malaise, abdominal pain, or nausea. The timing of symptoms with recently begun HDS will suggest a potential causative link. At this earliest stage, however, the clinician must specifically ask about use of HDS, as many may not volunteer this information to their health care providers without prompting.
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Just as with a DILI diagnosis, making a diagnosis of hepatotoxicity due to HDS requires that other causes, either alternative or pre-existing of liver injury be excluded, including anatomical, infectious, autoimmune, metabolic, ischemic, alcoholic, and inherited processes. Comprehensive serological evaluation and hepatic imaging are used in this process of exclusion.
The respective presentation of liver injury from many pharmaceuticals has been well described in the medical literature. The LiverTox website houses a large number of drugs and descriptions of their respective hepatotoxicity presentations. 42 Such descriptions help the clinician to establish the association between a hepatotoxic event and the drug with confidence. Unfortunately, there are only a few situations where the phenotype of liver injury due to HDS is so typical that an association between clinical presentation and a product can be made with the same degree of confidence as pharmaceuticals. Anabolic steroidal com- work has shown that detecting the genetic sequences of botanicals through barcoding may be of great value to verify ingredients of HDS. 63 How such technology can be used to predict or prevent end-organ injury has yet to be determined. Causality assessment is the systematic or semiquantitative approach to identify an agent as a cause for end-organ injury. This is used commonly in the research setting and for published case reports. Formal assessments were designed with pharmaceuticals in mind and several have been applied to DILI. [64] [65] [66] [67] None were crafted specifically for liver injury from HDS, although experience exists with several approaches. The Naranjo system has 68 been used for causality assessment with natural products. 69 However, it has limited specificity for hepatic reactions. The Roussel Uclaf Causality Assessment Method (RUCAM) was crafted for hepatic adverse reactions from pharmaceuticals, 64, 65, 70 and has been used in cases of liver injury induced by HDS quite commonly. The RUCAM assigns points based on the clinical features of a case. However, limitations of this scale when applied to the evaluation of liver injury from HDS have been highlighted. Specifically, an important component of the RUCAM requires an assessment of an agent's labeled reactions, and the literature published about hepatic reactions. Unfortunately, in the case of HDS, the literature is immature and of insufficient quality to fulfill this RUCAM component with confidence in most circumstances.
In another component of the RUCAM, a lower score is awarded in the setting of more than a 90-day period of exposure prior to the onset of injury. However, the inherent variability of botanicals means that different batches of the same product may have different compositions. Hence, latency as a factor in determining the causal association between an agent and liver injury must be thought of differently with HDS than with pharmaceuticals. Given the lack of verifiable standards in product quality and composition, it is entirely possible, if not probable, that a natural product may vary over time, even if marketed under the same label. Furthermore, causality assessment is confounded by the fact that patients may be taking a single product with single or multiple ingredients, or multiple products concurrently.
The Maria and Victorino Scale represents a modification of the RUCAM. 66 Its special feature is that it incorporates extrahepatic manifestations of disease that may hint at an autoimmune pathophysiological basis. This score seems to perform less well in causality assessment in most instances of DILI 71 and has not been used to any great extent in the assessment of liver injury due to HDS or pharmaceuticals. Finally, the expert opinion process represents the standard approach used by the DILIN, including the adjudication of injury due to HDS. 72 Unlike the above-mentioned scoring systems, the expert opinion approach allows the assessors a greater degree of latitude in making their decisions on causality. Specifically, all clinical details can be taken into account in determining the attribution of liver injury to an agent. Even this approach, however, remains confounded by factors unique to HDS as discussed above.
Given the lack of a causality assessment approach that is perfectly suited to and validated for the nuances of HDS, the DILIN attempted to craft an approach that would perform more reliably in this situation. The process, built upon the expert opinion approach routinely used by the DILIN, puts greater emphasis on the complexity of HDS, the experts' perception of the quality of the available literature and personal experience with injury due to the HDS in question. In a small test-retest reliability study, this approach performed with modest accuracy (weighted kappa statistic 0.53, 95% confidence interval [CI] 0.20-0.86). 73 Given this performance, a change in the DILIN's expert opinion approach to causality assessment for HDS was not adopted. However, the challenges remain and merit further study. Until a process that is demonstrably more reliable for liver injury due to HDS is developed, the assessment of causality is best undertaken with the RUCAM or expert opinion process, as has been proposed by others.
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Hepatotoxicity due to HDS: Specific Agents, Uses, and Injury Phenotype ►Table 3 outlines the name, common usages, suggested toxic mechanism, clinical presentation, and liver histology of several HDS linked to hepatotoxicity. The salient features of a chosen few that are more likely to be encountered in clinical practice are discussed in this section as well. The reader is referred to other excellent reviews on hepatotoxicity due to HDS for more details on other products.
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As for intended uses, we emphasize that there is no widely accepted classification schema or nomenclature for HDS, many of which are marketed as mixtures of various ingredients, as opposed to single herbs. In fact, in the DILIN's experience, most products that caused liver injury were proprietary blends, not single herbs. Therefore, in a recent presentation of its data, the DILIN assigned HDS that had been implicated in liver injury to categories based on their purported benefits or main marketed uses (►Table 4). This categorization takes into account that many different ingredients often are combined in a given product to achieve a desired effect. Although not a scientific schema, these categories allow clinicians, researchers, and consumers to group HDS for comparison purposes, and to facilitate recognition of clinical presentations that may be common to some HDS. For example, the products generally used for bodybuilding or muscle enhancement lead to an injury that is characteristic, with prolonged jaundice, pruritus, minimal inflammation, and complete recovery. A fundamental problem with any categorization scheme based on purported uses is that some, if not most HDS are marketed for more than one purpose, and are not mutually exclusive.
Ayurvedic Herbs. Traditional medical therapies are commonly used in India for various purposes. These have been linked to both acute and chronic hepatitis. Contamination with heavy metals 54, 56 has been demonstrated. However, whether the contamination was the cause for injury has not been proven. Androgenic Anabolic Steroids. Liver injury resulting from androgenic anabolic steroids runs the spectrum of space occupying lesions to the more typical cholestatic hepatitis.
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Many reports of products used for bodybuilding and muscle enhancement as a suspected cause for liver injury have been published. 45, 46, 79, 80 Some have been proven to be tainted with anabolic steroids. 46 Most reported injuries from these products is so typical that the clinical appearance of protracted jaundice in young men taking these agents has become pathognomonic. While the injury is typically cholestatic, the most recent report of hepatotoxicity resulting from performance enhancers suggested that up to a third may be more hepatocellular in nature.
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Black Cohosh. Commonly used for menopausal symptoms, this product has been named in numerous reports of attributable liver injury, [82] [83] [84] [85] [86] [87] [88] with at least one report of adulteration. 89 This herb has also been reported to produce an autoimmune-type liver injury. 86, 87 Severe liver injury leading to transplantation also has been reported.
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Chaparral. Used for various reasons (e.g., bronchitis, joint pain, weight loss), this herb derived from the creosote bush has been associated with severe liver injury and liver failure.
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Green Tea Extract. Commonly consumed, this agent is often extracted and formed into a more potent substance and is found in many different HDS. Thought to induce oxidative liver injury, several lines of evidence build a convincing case for its hepatotoxic potential. Specifically, toxicity demonstrated in animal studies 94 and human positive rechallenge cases 95, 96 are most compelling.
Chinese Herbal Remedies. These encompass a wide range of products used for various purposes, with weight loss (Ma- [107] [108] [109] [110] [111] [112] Warnings about the use of Kava have been published in the United States and several other countries, and it has been the subject of careful safety reviews.
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Pyrrolizidine Alkaloids. Found in comfrey tea, pyrrolizidine alkaloids induce injury to the sinusoidal epithelium, leading to a Budd-Chiari type picture, with hepatomegaly and ascites. The phenotype is so typical as to be pathognomonic, if in consistent temporal proximity to ingestion of pyrrolizidine alkaloids.
Usnic Acid. Used as an ingredient in weight-loss products, this product is known to uncouple membrane potential and thus induce oxidative stress and cell injury. 114 Liver injury cases, including some resulting in liver transplantation, led to removal of some usnic acid containing products from the market.
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Vitamin A. Known for its dose-dependent hepatotoxicity, the spectrum of injury can range from mild liver test elevations with steatosis, to necrosis. 118, 119 Injury usually occurs after exceeding 50,000 IU per day.
Prevention
Given the current regulatory milieu, the most effective prevention of liver injury due to HDS is awareness among consumers and providers that they have the capacity to cause hepatotoxicity. In addition, health care providers must keep in mind that symptoms associated with liver injury may be protean.
An assessment of whether current regulation is adequate to protect the consumer from injury due to HDS is in order. Preclinical testing would give better assurance of safety. Verification of contents prior to and after marketing would give confidence that product labels accurately reflect contents. On a global scale, the WHO's effort to harmonize regulation and safety standards for herbal medicines should serve as a common platform. 
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Conclusions and Future Directions
The premise that HDS are safe must be challenged, as there is ample evidence to the contrary. Achieving a culture of safety in the HDS industry will emerge only after the mounting evidence for injury from several HDS is recognized and a new agenda for research and regulation is developed. Such an agenda must take into account the varying regulatory approaches to HDS across the globe, as well as the varying uses as therapeutic agents, performance and appearance enhancers, and as agents to promote well-being. One of the most pressing needs is for the development of a standard and consistently applied nomenclature for HDS, recognized by all stakeholders, including clinicians, researchers, regulators, and manufacturers. Given the ease of access to HDS, the nomenclature system must be relevant and understandable to the consumer. With a standard system of categorizing HDS, associating injury phenotypes with product types becomes more feasible.
There is also a need to attain a more complete understanding of the epidemiology of liver injury attributable to HDS. Despite numerous reports in the literature, the impact of drug-and dietary supplement-induced hepatotoxicity on public health is unclear, as there are no accurate estimates of the incidence or prevalence of injury. This baseline information ensures that the appropriate resources can be allocated to research, and that regulation is proposed to protect what may be a large segment of the population.
Analysis of product labels reveals their complexity and multiplicity of ingredients. In fact, in the DILIN's experience, a review of listed ingredients revealed that there are more than 20 ingredients in most HDS implicated in liver injury (unpublished data). Identifying the actual ingredient responsible for injury would require a painstaking analytical approach to single out each constituent and perform formal toxicological analysis. A more feasible approach, as the DILIN plans, is to amass products implicated in liver injury and conduct a frequency analysis for commonly occurring ingredients, or combinations of ingredients. In this way, ingredients can be selected as possibly the cause for injury and subjected to formal toxicology testing.
As it is not required for HDS to undergo preclinical (in vitro and animal) and human clinical testing, such analyses prior to marketing typically are absent. Rather, less rigorous assessments of safety are used to support a product's entry into the market. Hence, product variability, unpredictable pharmacokinetics, interaction among ingredients within a given product, and the effect of HDS on prescribed medications are important concerns. A better understanding of these issues would require detailed and complex chemical analysis followed by formal clinical pharmacology and toxicity testing. To make certain that the findings of such analyses led to safer products, findings would have to be coupled with new regulation which establishes product standards that are then enforced by oversight bodies.
It is likely that voluntary reporting of adverse events from use of HDS is infrequent given the consumer's presumption of safety as well as reluctance to divulge use of HDS to physicians. Hence, measures to promote postmarketing pharmacovigilance are needed. LiverTox, 42 an authoritative compendium of marketed drugs and their associated liver injuries, will continue to be developed as a resource for liver injury due to HDS. Health care providers must also make use of a voluntary reporting mechanism for suspected cases of hepatotoxicity due to HDS. In the United States and abroad, the FDA's MEDWATCH system (http://www.fda.gov/Safety/ MedWatch/default.htm) is a valuable tool.
As is the case with several drugs, 120,121 a genetic basis for injury attributable to some HDS can reasonably be hypothesized. For example, liver injury due to bodybuilding products, 45, 46, 78 shown in some reported cases to be tainted with undeclared steroids, leads to a characteristic clinical presentation with prolonged jaundice, initially with hepatocellular injury in some cases, 81 but with evolution to a bland cholestasis, and complete recovery, almost exclusively in young men. Although some of the reproducibility of the injury pattern may result from the demographic of use, commonly being young men, it is also possible that a common genetic mutation or polymorphism in a bile salt transporter may explain such a characteristic picture of injury. Finally, even with stringent regulation, scrupulous adherence, and vigilant oversight, injury from HDS will occur as it does with conventional medications. Therefore, biomarker development to predict liver injury or predict it at an early stage should be pursued. Biomarkers for liver injury attributable to HDS have been detected with alkaloids and germander, 122, 123 providing rationale for additional research in this area.
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